Lantern Pharma Secures EU Patent Allowance For LP-284, Expanding Global IP For B-Cell Lymphoma Therapy

Author: Benzinga Newsdesk | July 21, 2025 07:21am

• The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico.
• LP-284 has the potential to address B-cell lymphomas and other B-cell driven malignancies addressing a $4+ billion annual market need
• LP-284 is in an active Phase 1 trial in the US focused on lymphomas and other B-cell cancers with a potential completion in late 2025

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent, expected to be granted in the coming months with exclusivity through early 2039, strengthens Lantern's global intellectual property (IP) portfolio and supports the development and commercialization path for LP-284, a novel therapy in development for relapsed or refractory non-Hodgkin's lymphoma (NHL), including mantle cell lymphoma (MCL) and high-grade B-cell lymphomas (HGBL).

LP-284, a next-generation acylfulvene, was optimized using Lantern's RADR® platform, which identified its synthetically lethal mechanism targeting cancer cells with DNA damage repair deficiencies. Currently in a Phase 1 clinical trial (NCT06132503), LP-284 has demonstrated preclinical potential in addressing aggressive NHL subtypes, including MCL and double-hit lymphoma (DHL). The drug candidate has earned Orphan Drug Designations from the U.S. FDA for both MCL and HGBL, highlighting its role in tackling rare cancers with significant unmet needs.

Expanding Global Patent Protection

The EU patent complements a composition of matter patent granted in Japan (June 2024) and the U.S. (April 2023), with additional patent allowances grants in India and Mexico, and applications pending in China, Australia, Canada, and Korea. This expanding international IP portfolio positions LP-284 for global commercialization and strategic partnerships.

Posted In: LTRN